Patents Examined by Jeanine Goldberg
  • Genetic markers for diagnosis of tuberculosis caused by
    Patent number: 10597734
    Abstract: The application is related to novel signature sequences for diagnosis of Mycobacterium tuberculosis in clinical samples with 100% specificity and a very high degree of sensitivity.
    Type: Grant
    Filed: December 1, 2014
    Date of Patent: March 24, 2020
    Assignees: EUROPEAN MOLECULAR BIOLOGY LABORATORY, KUSUMA SCHOOL OF BIOLOGICAL SCIENCES INDIAN INSTITUTE OF TECHNOLOGY
    Inventors: Syed Asad Rahman, Javeed Ahmad, Nasreen Z Ehtesham, Seyed E Hasnain
  • Detecting gastric neoplasm
    Patent number: 10597733
    Abstract: Provided herein is technology relating to detecting neoplasia and particularly, but not exclusively, to methods, compositions, and related uses for detecting premalignant and malignant neoplasms such as gastric cancer.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: March 24, 2020
    Assignees: Mayo Foundation for Medical Education and Research, Exact Sciences Development Company, LLC
    Inventors: David A. Ahlquist, William R. Taylor, John B. Kisiel, Tracy C. Yab, Douglas W. Mahoney, Hatim T. Allawi
  • Recurrent gene fusions in cutaneous CD30-positive lymphoproliferative disorders
    Patent number: 10590488
    Abstract: Provided herein are kits, compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to recurrent gene fusions (e.g., recurrent translocations involving TYK2) as diagnostic markers and clinical targets for cutaneous CD30-positive lymphoproliferative disorders (e.g., lymphomatoid papulosis; primary cutaneous anaplastic large cell lymphoma).
    Type: Grant
    Filed: January 29, 2016
    Date of Patent: March 17, 2020
    Assignee: The Regents of the University of Michigan
    Inventors: Kojo Elenitoba-Johnson, Mark J. Kiel, Delphine Rolland, Bryan L. Betz, Nathanael G. Bailey, Thirunavukkarasu Velusamy, Megan Lim
  • Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof
    Patent number: 10563263
    Abstract: The present invention provides compositions and methods based on genetic polymorphisms that are associated with response to statin treatment, particularly for reducing the risk of cardiovascular disease, especially coronary heart disease (such as myocardial infarction) and stroke. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents and kits for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents and kits for their detection.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: February 18, 2020
    Assignee: Celera Corporation
    Inventor: Dov Shiffman
  • Method of predicting risk of recurrence of cancer
    Patent number: 10557175
    Abstract: A method for predicting risk of recurrence of cancer in an individual with cancer, the method comprising a step of assaying a cancer sample from the individual for positive expression of at least two genes or proteins encoded by those genes selected from the group consisting of FOXM1, UHRF1, PTTG1, E2F1, MYBL2, HMGB2, ATAD2, E2F8, ZNF367 and TCF19, wherein positive expression of the at least two genes correlates with increased risk of recurrence of cancer compared with an individual who does not exhibit positive expression of the at least two genes or proteins encoded by those genes.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: February 11, 2020
    Assignees: THE PROVOST, FELLOWS, SCHOLARS AND OTHER MEMBERS OF BOARD OF TRINITY COLLEGE DUBLIN, UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN
    Inventors: Adrian Bracken, Fiona Lanigan, William Gallagher
  • Thromboembolic disease markers
    Patent number: 10557170
    Abstract: The invention relates to a method for a more appropriate thromboembolic event risk assessment based on the presence of different genetic variant. The invention also relates to a method for determining the risk of suffering a thromboembolism disease by combining the absence or presence of one or more polymorphic markers in a sample from the subject with conventional risk factors for thromboembolism as well as computer-implemented means for carrying out said method.
    Type: Grant
    Filed: July 17, 2017
    Date of Patent: February 11, 2020
    Assignee: Gendiag.exe, S.L.
    Inventors: Eduardo Salas, José Manuel Soria, Miroslava Ogorelkova, Roberto Elosua Llanos, Joan Vila, Sergio Castillo Fernandez
  • Method and kit for determining whether a subject shows an immune response
    Patent number: 10550430
    Abstract: The present invention relates to a kit and a method for determining whether a subject shows an immune response against an antigen.
    Type: Grant
    Filed: October 24, 2014
    Date of Patent: February 4, 2020
    Assignees: BIONTECH DIAGNOSTICS GMBH, TRON—TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG—UNIVERSITAT MAINZ GEMEINNUTZIGE GMBH
    Inventors: Ugur Sahin, Michael Schäfer, Marta Magdalena Faryna, Tana Omokoko, Lisa Hebich, Petra Simon, Annett Reichardt, Özlem Öz
  • Polymorphism in the Apo(a) gene predict responsiveness to acetylsalicylic acid treatment
    Patent number: 10550433
    Abstract: This invention relates to nucleotide polymorphisms in the human Apo(a) gene and to the use of Apo(a) nucleotide polymorphisms in identifying whether a human subject will respond or not to treatment with acetylsalicylic acid.
    Type: Grant
    Filed: April 3, 2017
    Date of Patent: February 4, 2020
    Assignees: The Brigham and Women's Hospital, Inc., Celera Corporation
    Inventors: Paul M. Ridker, Daniel Chasman, Dov Shiffman
  • Methods for reducing drug-induced liver injury
    Patent number: 10533049
    Abstract: The present disclosure provides methods of treating a patient with infliximab or alternative therapies to reduce the risk of developing, and/or severity of, an adverse drug reaction such as drug-induced liver injury. The methods include identifying patients at risk for developing DILI by determining the presence or absence of one or more HLA alleles in the patients.
    Type: Grant
    Filed: May 8, 2019
    Date of Patent: January 14, 2020
    Assignee: TEN PEAKS LLC
    Inventors: Sundar Srinivasan, Christina Chow
  • Biomarkers for colorectal cancer
    Patent number: 10526659
    Abstract: Biomarkers and methods related to microbiota for predicting the risk of a disease, particularly colorectal cancer (CRC), are described.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: January 7, 2020
    Assignees: BGI Shenzhen Co., Limited, BGI Shenzhen
    Inventors: Qiang Feng, Dongya Zhang, Longqing Tang, Jun Wang
  • Methods for reducing drug-induced liver injury
    Patent number: 10519227
    Abstract: The present disclosure provides methods of treating a patient with infliximab or alternative therapies to reduce the risk of developing, and/or severity of, an adverse drug reaction such as drug-induced liver injury. The methods include identifying patients at risk for developing DILI by determining the presence or absence of one or more HLA alleles in the patients.
    Type: Grant
    Filed: May 8, 2019
    Date of Patent: December 31, 2019
    Assignee: TEN PEAKS LLC
    Inventors: Sundar Srinivasan, Christina Chow
  • Methods for reducing drug-induced liver injury
    Patent number: 10519228
    Abstract: The present disclosure provides methods of treating a patient with infliximab or alternative therapies to reduce the risk of developing, and/or severity of, an adverse drug reaction such as drug-induced liver injury. The methods include identifying patients at risk for developing DILI by determining the presence or absence of one or more HLA alleles in the patients.
    Type: Grant
    Filed: May 8, 2019
    Date of Patent: December 31, 2019
    Assignee: TEN PEAKS LLC
    Inventors: Sundar Srinivasan, Christina Chow
  • Diagnosis of hereditary spastic paraplegias (HSP) by detection of a mutation in the KIAA1840 gene or protein
    Patent number: 10519503
    Abstract: An ex vivo method of diagnosing or predicting an hereditary spastic paraplegias (HSP) in a subject is provided which comprises detecting a mutation in the KIAA1840 gene or protein (spatacsin), wherein that mutation is indicative of an hereditary spastic paraplegias (HSP).
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: December 31, 2019
    Assignee: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Hamid Azzedine, Alexis Brice, Giovanni Stevanin, Filippo Santorelli, Paola Denora
  • Primer pair, kit and method for detecting anaplasma platys
    Patent number: 10513740
    Abstract: Primer pair, kit and method for detecting Anaplasma platys are disclosed. The primer pair includes a forward primer and a reverse primer, and the kit includes the primer pair and a probe. The forward primer has a sequence of SEQ ID NO: 1, the reverse primer has a sequence of SEQ ID NO: 2, and the probe has a sequence of SEQ ID NO: 3.
    Type: Grant
    Filed: August 16, 2017
    Date of Patent: December 24, 2019
    Assignee: DELTA ELECTRONICS INT'L (SINGAPORE) PTE LTD
    Inventors: Yong Zhang, Chih-Yu Chao
  • Method to diagnose malignant melanoma in the domestic dog
    Patent number: 10513738
    Abstract: This disclosure is directed to the discovery of an improved method to diagnose malignant melanoma of the oral cavity in the dog.
    Type: Grant
    Filed: July 24, 2015
    Date of Patent: December 24, 2019
    Assignee: North Carolina State University
    Inventor: Matthew Breen
  • Chromosomal assessment to differentiate histiocytic malignancy from lymphoma in dogs
    Patent number: 10501806
    Abstract: This invention relates generally to the discovery of an improved method to differentiate histiocytic malignancy from lymphoma or hemangiosarcoma in dogs.
    Type: Grant
    Filed: April 15, 2015
    Date of Patent: December 10, 2019
    Assignee: North Carolina State University
    Inventor: Matthew Breen
  • Primer pair, kit and method for detecting
    Patent number: 10494680
    Abstract: Primer pair, kit and method for detecting Babesia gibsoni are disclosed. The primer pair includes a forward primer and a reverse primer, and the kit includes the primer pair and a probe. The forward primer has a sequence of SEQ ID NO: 1, the reverse primer has a sequence of SEQ ID NO: 2, and the probe has a sequence of SEQ ID NO: 3.
    Type: Grant
    Filed: August 23, 2017
    Date of Patent: December 3, 2019
    Assignee: DELTA ELECTRONICS INT'L (SINGAPORE) PTE LTD
    Inventors: Yong Zhang, Chih-Yu Chao
  • Chromosomal assessment to diagnose urogenital malignancy in dogs
    Patent number: 10450612
    Abstract: This invention is directed to a method of diagnosing bladder cancer in dogs.
    Type: Grant
    Filed: November 14, 2014
    Date of Patent: October 22, 2019
    Assignee: North Carolina State University
    Inventor: Matthew Breen
  • Detecting esophageal disorders
    Patent number: 10435755
    Abstract: Provided herein is technology for esophageal disorder screening and particularly, but not exclusively, to methods, compositions, and related uses for detecting the presence of esophageal disorders (e.g., Barrett's esophagus, Barrett's esophageal dysplasia, etc.). In addition, the technology provides methods, compositions and related uses for distinguishing between Barrett's esophagus and Barrett's esophageal dysplasia, and between Barrett's esophageal low-grade dysplasia, Barrett's esophageal high-grade dysplasia, and esophageal adenocarcinoma within samples obtained through endoscopic brushing or nonendoscopic whole esophageal brushing or swabbing using a tethered device (e.g. such as a capsule sponge, balloon, or other device).
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: October 8, 2019
    Assignees: Exact Sciences Development Company, LLC, Mayo Foundation for Medical Education and Research
    Inventors: David A. Ahlquist, William R. Taylor, John B. Kisiel, Douglas W. Mahoney, Tracy C. Yab, Graham P. Lidgard, Hatim T. Allawi
  • Method for detecting methylation of colorectal cancer specific methylation marker gene for colorectal cancer diagnosis
    Patent number: 10428390
    Abstract: The present disclosure relates to a method for detecting methylation of the bowel-cancer-specific methylation marker GPM6A (NM_201591, glycoprotein M6A) gene in order to diagnose bowel cancer, and more specifically relates to a method for providing information for diagnosing bowel cancer by detecting the methylation of a bowel-cancer-specific marker gene that is specifically methylated in bowel cancer cells. The method for detecting methylation and a diagnostic composition, kit and nucleic-acid chip according to the present disclosure can be used to advantage in diagnosing bowel cancer more accurately and quickly than by normal methods as they permit bowel cancer to be diagnosed at the initial genetic transformation step and so allow early diagnosis.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: October 1, 2019
    Assignee: GENOMICTREE, INC.
    Inventors: Sung Whan An, Tae Jeong Oh